Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two complete response letters (CRL) from the FDA. While the agency issued the ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

The signs of a dangerous blood clot can vary depending on its location. Some people may also not experience any symptoms.

Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER ...

If your allergies leave you feeling lightheaded or cause chest pain, alert your doctor immediately, Nagarajan said. It could ...

That response can lead to chronic inflammation ... Dr. Sairaman Nagarajan, a physician editor at The Merck Manuals and an adjunct faculty member at SUNY Downstate Health Sciences, was lead ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...